Pedro Gonzalez Menedez. University of Oviedo (Spain)
Dr. Pedro Gonzalez Menedez fulfilled his PhD training in Dr. Rosa Sainz’s group at the University of Oviedo. His thesis, supported by the FPU program (Spanish Government), focused on GLUT transporters' role during prostate cancer progression. On the one hand, he described for the first time the expression of the insulin-dependent GLUT4 in prostate cancer cells (Endocrinology, 2014). In a second article, he found that androgen-sensitive cells are more resistant to glucose deprivation-dependent cell death by overexpressing GLUT1 and protecting oxidative stress by maintaining glutathione levels (Redox Biology, 2018). As part of his predoctoral training, he was selected for a European Association for Cancer Research short stay award in the group of Naomi Taylor in the Institut de Genétique Moléculaire de Montpellier (IGMM) at the Centre National de la Recherche Scientifique (CNRS). In 2018, he joined her group as a postdoctoral researcher under the supervision of Sandrina Kinet. First, he was supported by the Clarin-COFUND EU Program ("Gobierno del Principado de Asturias", Marie Curie Action), and then through an NIH PO1 grant. He studied the impact of mitochondrial oxidative stress during late terminal erythropoiesis (Cell Reports, 2021), and the role of the hypusinated-eIF5A in mitochondrial activity during erythropoiesis (Blood, 2023). In 2022, he rejoined the University of Oviedo with a “María Zambrano” grant into the “Redox biology and metabolism in cancer” team. Since 2023, he is a researcher funded by the “Ramón y Cajal” program (Spanish Government).